-
Rimonabant (also
known as SR141716;
trade names Acomplia, Zimulti) is an
anorectic antiobesity drug
approved in
Europe in 2006 but was
withdrawn worldwide...
-
receptor antagonists. The
first CBR
inverse agonist,
rimonabant, was
described in 1994.
Rimonabant blocks the CB1
receptor selectively and has been shown...
- at the CB1
cannabinoid receptor. AM-251 is
structurally very
close to
rimonabant; both are
biarylpyrazole cannabinoid receptor antagonists. In AM-251,...
-
oxaloacetate supplements had no
effect on
lifespan in
healthy laboratory mice.
Rimonabant (Acomplia) is an anti-obesity drug
initially approved for use in the European...
- depression, and
thoughts of
suicide in
patients treated with the now-withdrawn
rimonabant,
another CB1
antagonist that was also
under development by Sanofi-Aventis...
- seen with an antagonist. An
example is the
cannabinoid inverse agonist rimonabant. A
superagonist is a term used by some to
identify a
compound that is...
- cannabis),
increased appetite. However, some
drugs in this
class such as
rimonabant were
withdrawn or
ceased development to
concerns about mental health and...
- The
antihypertensive effect of
Spilanthol was
blocked by CB1
antagonist Rimonabant and TRPV1
antagonist Capsazepine suggesting Spilanthol mediates some activity...
-
drugs that were ever
approved by the FDA. Some of them (lumiracoxib,
rimonabant, tolrestat,
ximelagatran and ximelidine, for example) were
approved to...
-
adverse cardiovascular risk profile. Similarly, the
appetite suppressant rimonabant (a
cannabinoid receptor antagonist) had to be
withdrawn when it was linked...
